A case of self-ingestion of brodifacoum that resulted in spontaneous intra-abdominal haemorrhage, circulatory shock, rhabdomyolysis and acute renal failure is reported. Current knowledge and management of superwarfarin poisoning are discussed.
Brodifacoum is a readily available second generation anticoagulant rodenticide (superwarfarin). Due to its prolonged action, poisoning can produce a coagulopathy lasting many months.
CASE REPORT
A 26-year-old male student was brought to the Emergency Department of another hospital having been found by relatives slumped on the floor at home, agitated and semiconscious. On arrival at hospital he was unconscious with a Glasgow Coma Score (GCS) of 3. The carotid pulse was weakly palpable. The abdomen was distended and there was bleeding from the mouth and urethra. He was intubated and ventilated with 100% oxygen. Following an infusion of 1.6 litres of Hartmann's solution, 2.5 litres of polygeline (Haemaccel) and six units of packed red blood cells, the blood pressure was 150/85 mmHg although there was no improvement in his GCS. Investigations prior to resuscitation showed a haemoglobin concentration of 4.6 g/dl, a severe metabolic acidosis (pH 6.65, base excess -30 mmol/l) and a coagulopathy (PT and APTT>150s). A mobile abdominal ultrasound examination showed 200 ml free fluid in the subphrenic space and a large retroperitoneal mass in the midline over the inferior vena cava and aorta. Anticoagulant poisoning was suspected and Vitamin K 10 mg administered intravenously. Following stabilization he was transferred to this hospital for further management.
A CT scan of the abdomen confirmed free intraperitoneal blood and a large haematoma in the mesentery. A cranial CT scan performed at the same time was normal with no evidence of an intracerebral bleed. An emergency laparotomy disclosed a massive mesenteric haematoma with free intraperitoneal blood. The source of the blood loss was not identified. The measured blood loss was 4500 ml. Intraoperatively twelve units of fresh frozen plasma (FFP) and six units of red blood cells were transfused. He remained haemodynamically stable throughout the procedure and following correction of the coagulopathy there was no evidence of ongoing bleeding. Postoperatively he was transferred to the Intensive Care Unit and ventilated overnight. A further five units of packed red blood cells were transfused. The next day he was awake with a GCS of 15 and was extubated uneventfully. The serum creatine kinase (CK) peaked on day 2 at 15,600 units/l associated with detectable levels of urinary myoglobin. Despite a rise in the serum creatinine to 0.44 mmol/l the urine output was well maintained. The CK rapidly fell to normal levels over the next five days and the creatinine was normal by day 10. There was no muscle trauma or tenderness. A warfarin assay and disseminated intravascular coagulation (DIC) screen were negative.
Further questioning revealed a history of depression associated with the stress of a final thesis that was due for completion. He initially strongly denied having taken any coumarin-like medications before finally confessing to the ingestion of two packets of "Mortein Rat Kill®" on two occasions some days prior to admission. This rodenticide contains the superwarfarin brodifacoum.
Coagulation remained abnormal and in the first week he received 53 units of FFP to maintain a pro-Anaesth Intens Care 1997; 25: 707-709 Superwarfarin (Brodifacoum) Poisoning thrombin time below 30 seconds. At the same time he received intramuscular vitamin K1 initially at a dose of 50 mg/day and subsequently increased to 100 mg/day. His recovery was complicated by bilateral basal consolidation and pleural effusions, haematuria, a pseudomonas urinary tract infection, and a small subdural haematoma which did not require evacuation.
He was transfused a total of 110 units of FFP over a period of 19 days. He was discharged from hospital five weeks after his initial presentation on oral vitamin K1 100 mg/day. His clotting studies at this time were normal.
DISCUSSION
Brodifacoum was first described in 1975 by Hadler and Shadbolt 1 . It is one of several 4-hydroxycoumarin derivatives, termed superwarfarins, which were developed as rodenticides against warfarin-resistant rats. Other superwarfarins in this group are difenacoum and bromadiolone. The related inandione group contains diphacinone, pindone, and chlorphacinone. Like warfarin, these compounds inhibit vitamin K epoxide reductase resulting in a lack of vitamin K. Vitamin K is required for the γ-carboxylation of clotting factors II (prothrombin), VII, IX and X.
The γ-carboxylglutamic acid residue conveys calcium binding properties to these proteins. This is essential for their assembly into an efficient catalytic complex. In the presence of coumarins this metal stabilized conformational change is disrupted producing ineffective coagulation 3 .
The superwarfarins are approximately 100 fold more potent than warfarin in their inhibition of vitamin K epoxide reductase. They are characterized by a long in vivo half-life, high fat solubility leading to a large volume of distribution and high concentrations in the liver, and slow plasma elimination. The plasma elimination curve for brodifacoum is biphasic with the terminal elimination phase of the curve representing a "deep" compartment shown in animals and a fatal human case to be the liver 3, 10 . Concentrations in the liver are twenty times greater than the plasma levels. The terminal plasma half-life has been variously reported to be between 20 and 62 days, compared with 37±15 hours for warfarin 3 .
"Mortein Rat Kill®" contains brodifacoum 0.005% in a wheat food base. Along with many other proprietary rodenticides, it is readily available at a low cost in supermarkets. The total calculated ingested dose of brodifacoum in this case was approximately 13 mg. Ingested doses in previously reported cases that have resulted in coagulopathy have ranged from 1.0 to 75 mg 4 .
Superwarfarin poisoning is usually due to self ingestion and is generally seen in young adults with suicidal intent. Males outnumber females and denial is a common feature. Abnormal coagulation results in nasal and gingival bleeding, haematuria, melaena and easy bruising. More serious and life-threatening presentations include compartment syndrome, pulmonary haemorrhage with respiratory failure and subarachnoid haemorrhage [5] [6] [7] [8] [9] . Three fatal adult cases have been reported 7, 9, 10 . This is the first report of spontaneous intra-abdominal haemorrhage complicating brodifacoum poisoning. Due to the size and colour of rodenticide pellets, children can mistake them for sweets. To thwart accidental ingestion, the pellets often contain the bitter tasting compound Bitrex. As only small quantities are consumed the outcome in children is usually benign. There is a single report of superwarfarin administration by a parent in a case of Munchausen syndrome by proxy 11 .
Because the half-life of Factor VII is the shortest (approximately six hours), anticoagulation effects may be seen as early as eight to twelve hours after ingestion; however, peak effects are usually not seen for one to three days because of the longer half-lives of some of the other vitamin K dependent factors (24-60 hours). This delayed anticoagulant effect may be wrongly interpreted as a lack of efficacy by individuals contemplating suicide, resulting in further superwarfarin ingestion some days later. Apparently this was the case with this patient who on two occasions prior to admission ingested brodifacoum. The initial prothrombin time of greater than 150 seconds indicated a severe coagulopathy. Although the source of bleeding was not identified at laparotomy, a vascular anomaly within the mesentery was suspected. The sudden and enormous intra-abdominal haemorrhage rapidly resulted in circulatory shock, loss of consciousness and profound biochemical abnormalities. The rise in the serum creatine kinase and myoglobinuria indicated a degree of rhabdomyolysis. This presumably resulted from severe tissue hypoxia during the period of profound hypotension producing muscle ischaemia. There was no evidence of compartment syndrome or muscle trauma and the period of immobility before being found by relatives was considered too short to explain the rise. Coumarins have not been reported to be a cause of rhabdomyolysis 12 . The non-oliguric renal failure that followed was thought to be due to acute tubular necrosis.
Although coumarin poisoning was considered the cause of the clotting abnormality, the patient's vigorous denial and subsequent negative assay for warfarin delayed the diagnosis. A lack of a sustained response to fresh frozen plasma and vitamin K should alert practitioners to the possibility of superwarfarin ingestion. If a superwarfarin assay is unavailable, there are a number of laboratory tests that can help the clinician. To differentiate between an acquired factor deficiency and an inhibitor (e.g. brodifacoum), mixing studies can be performed. In this test, the patient's plasma is mixed with varying proportions of normal plasma. In the setting of a factor deficiency, adding 50% of normal plasma should correct the prothrombin time (PT) and activated partial thromboplastin time (APTT) to near control values. However, in the presence of an inhibitor of clotting factors, the addition of normal plasma fails to correct these coagulation studies. Another useful test is the assay of vitamin K metabolites in the serum. This can be used as a surrogate method of detecting the presence of coumarin compounds. In general, the vitamin K1-2,3 epoxide to vitamin K ratio reflects the degree of inhibition of vitamin K action. A reversal of the normal ratio indicates defective epoxide activity 13 . It is worth emphasizing that the superwarfarin agents are not detected in the serum warfarin assay. In specialized centres, a high-performance liquid chromatographic (HPLC) method is available for the analysis of indandione and 4-hydromycoumarin rodenticides in human serum 14 . This method has been successfully used to detect brodifacoum in covert poisoning in the absence of a history of ingestion 15 . Treatment is guided by the clinical situation. If significant haemorrhage occurs, transfusion of red blood cells and fresh frozen plasma are needed. Care should be taken if endotracheal intubation is required as this can precipitate bleeding. In those patients who are not yet anticoagulated emesis should be induced or gastric lavage with activated charcoal performed 16 . Phenobarbitone stimulates hepatic microsomes and is speculated to hasten the metabolism of warfarinlike drugs. It has been used in some cases of brodifacoum poisoning but is currently not recommended 7 . The specific antidote is vitamin K1 (phytonadione). Vitamin K3 (menadione), which is metabolized in the liver to phytonadione, is ineffective in correcting the coagulation abnormalities in superwarfarin poisoning even in patients with normal liver function 17 . Phytonadione is formulated in an emulsion of polyethoxylated fatty acid derivatives (Cremophor EL) and dextrose and can cause anaphylaxis when given intravenously 18 . It is therefore recommended that it be given intramuscularly or orally. Total daily require-ments vary, with reports of up to 200 mg/day being needed 19 . The prothrombin time is used to monitor response and fresh frozen plasma given as required or if clinically indicated. Vitamin K1 may need to be continued for up to 13 months 6,7 .
